Uveitis as a Result of MAP Kinase Pathway Inhibition

Abstract

We report the case of a patient treated with dabrafenib and trametinib (mitogen-activated protein kinase pathway inhibitors) for stage 3b cutaneous melanoma who developed bilateral uveitis. Although there have been reports of ocular side effects with this class of drugs, uveitis has not been previously reported to the best of our knowledge. This case indicates the wide range of side effects that can be seen with the newer targeted biological therapies.

Keywords

• Dabrafenib
• Trametinib
• Uveitis
• Melanoma